PCN71 - BUDGET IMPACT ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN BULGARIA

B Cell ◽

Impact Analysis ◽

Budget Impact ◽

Lymphoblastic Leukemia ◽

Budget Impact Analysis ◽

Cell Precursor ◽

PCN118 Budget IMPACT Analysis of Inotuzumab Ozogamicin for the Treatment of Adults with Relapsed or Refractory B-Cell Precursor ACUTE Lymphoblastic Leukemia in the Netherlands

Value in Health ◽

10.1016/j.jval.2020.08.255 ◽

2020 ◽

Vol 23 ◽

pp. S444

Author(s):

I. van Oostrum ◽

K. De Lameillieure ◽

T.A. Russell-Smith

Keyword(s):

The Netherlands ◽

B Cell ◽

Impact Analysis ◽

Budget Impact ◽

Lymphoblastic Leukemia ◽

Budget Impact Analysis ◽

Cell Precursor ◽

PCN77 - BUDGET IMPACT ANALYSIS OF BLINATUMOMAB FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA NEGATIVE RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN MEXICO

Value in Health ◽

10.1016/j.jval.2018.09.159 ◽

2018 ◽

Vol 21 ◽

pp. S27

Author(s):

M.E. Alva ◽

M. Ortíz ◽

B. Flores

Keyword(s):

B Cell ◽

Impact Analysis ◽

Pediatric Patients ◽

Budget Impact ◽

Lymphoblastic Leukemia ◽

Budget Impact Analysis ◽

Cell Precursor

Budget Impact Analysis Comparing Blinatumomab In The Treatment Of Adults With Philadelphia Chromosome-Negative Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (All) With Flag-Ida And Hyper CVAD

Value in Health ◽

10.1016/j.jval.2017.08.856 ◽

2017 ◽

Vol 20 (9) ◽

pp. A549

Author(s):

M Naranjo ◽

ME Alva ◽

I Muñoz

Keyword(s):

B Cell ◽

Impact Analysis ◽

Budget Impact ◽

Lymphoblastic Leukemia ◽

Philadelphia Chromosome ◽

Budget Impact Analysis ◽

Cell Precursor

Inotuzumab ozogamicin: a CD22 mAb–drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia

Drug Design Development and Therapy ◽

10.2147/dddt.s150317 ◽

2018 ◽

Vol Volume 12 ◽

pp. 2293-2300 ◽

Cited By ~ 20

Author(s):

Ilana R Yurkiewicz ◽

Lori Muffly ◽

Michaela Liedtke

Keyword(s):

B Cell ◽

Lymphoblastic Leukemia ◽

Cell Precursor ◽

Inotuzumab Ozogamicin ◽

Drug Conjugate

Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States

PharmacoEconomics ◽

10.1007/s40273-019-00812-6 ◽

2019 ◽

Vol 37 (9) ◽

pp. 1177-1193 ◽

Cited By ~ 6

Author(s):

Thomas E. Delea ◽

Xinke Zhang ◽

Jordan Amdahl ◽

Diana Boyko ◽

Franziska Dirnberger ◽

...

Keyword(s):

United States ◽

Cost Effectiveness ◽

B Cell ◽

Lymphoblastic Leukemia ◽

The United States ◽

Adult Patients ◽

Cell Precursor ◽

Use of inotuzumab-ozogamicin in a child with Down syndrome and refractory B-cell precursor acute lymphoblastic leukemia

Pediatric Blood & Cancer ◽

10.1002/pbc.27562 ◽

2018 ◽

Vol 66 (4) ◽

pp. e27562 ◽

Cited By ~ 2

Author(s):

Laura Murillo ◽

José Luis Dapena ◽

Pablo Velasco ◽

Cristina Díaz de Heredia

Keyword(s):

Down Syndrome ◽

B Cell ◽

Lymphoblastic Leukemia ◽

Cell Precursor ◽

PCN142 - COST-EFFECTIVENESS ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN BULGARIA

Value in Health ◽

10.1016/j.jval.2018.09.225 ◽

2018 ◽

Vol 21 ◽

pp. S38

Author(s):

S. Djambazov ◽

G. Slavchev ◽

M. Encheva-Malinova ◽

V. Varbanova ◽

M. Velchev ◽

...

Keyword(s):

Cost Effectiveness ◽

B Cell ◽

Lymphoblastic Leukemia ◽

Cost Effectiveness Analysis ◽

Cell Precursor ◽

Inotuzumab Ozogamicin ◽

Effectiveness Analysis

Decision letter for "High prevalence of MEF2D fusion in human B‐cell precursor acute lymphoblastic leukemia cell lines"

10.1002/hon.2762/v3/decision1 ◽

2020 ◽

Keyword(s):

B Cell ◽

Cell Lines ◽

Lymphoblastic Leukemia ◽

Leukemia Cell ◽

Cell Precursor ◽

Leukemia Cell Lines ◽

High Prevalence ◽

Human B Cell

Decision letter for "High prevalence of MEF2D fusion in human B‐cell precursor acute lymphoblastic leukemia cell lines"

10.1002/hon.2762/v1/decision1 ◽

2020 ◽

Keyword(s):

B Cell ◽

Cell Lines ◽

Lymphoblastic Leukemia ◽

Leukemia Cell ◽

Cell Precursor ◽

Leukemia Cell Lines ◽

High Prevalence ◽

Human B Cell

Faculty Opinions recommendation of IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725540965.793524754 ◽

2016 ◽

Author(s):

Jan Starý

Keyword(s):

Maintenance Therapy ◽

B Cell ◽

Prognostic Marker ◽

Lymphoblastic Leukemia ◽

Cell Precursor ◽

Independent Prognostic Marker ◽

Leukemia Group